Novogene Co., Ltd. (SHA:688315)

China · Delayed Price · Currency is CNY

14.34

-0.34 (-2.32%)

Sep 2, 2026, 3:00 PM CST

-9.36% (1Y)

Market Cap	5.95B -5.7%
Revenue (ttm)	2.28B +6.0%
Net Income	151.34M -23.4%
EPS	0.38 -20.5%
Shares Out	405.06M
PE Ratio	38.53
Forward PE	28.50
Dividend	0.05 (0.29%)
Ex-Dividend Date	Jun 10, 2026

Volume	5,454,783
Open	14.73
Previous Close	14.68
Day's Range	14.25 - 14.74
52-Week Range	11.46 - 18.24
Beta	0.71
Analysts	Strong Buy
Price Target	17.25 (+20.29%)
Earnings Date	Aug 26, 2026

About Novogene

Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 16S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcripto... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Employees 2,225

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688315

Full Company Profile

Financial Performance

In 2025, Novogene's revenue was 2.21 billion, an increase of 4.66% compared to the previous year's 2.11 billion. Earnings were 166.95 million, a decrease of -15.16%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 688315 stock is "Strong Buy." The 12-month stock price target is ¥17.25, which is an increase of 20.29% from the latest price.

Price Target

¥17.25

(20.29% upside)

Analyst Consensus: Strong Buy

Stock Forecasts